sr141716 has been researched along with n-(piperidin-1-yl)-5-(4-methoxyphenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caulder, T; Hoffman, AF; Horti, AG; Katoch-Rouse, R; Mukhin, AG; Pavlova, OA | 1 |
1 other study(ies) available for sr141716 and n-(piperidin-1-yl)-5-(4-methoxyphenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide
| Article | Year |
|---|---|
Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity.
Topics: Animals; Benzoxazines; Cannabinoids; Cerebellum; In Vitro Techniques; Ligands; Membrane Potentials; Morpholines; Naphthalenes; Nucleus Accumbens; Piperidines; Pyrazoles; Radioligand Assay; Rats; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Structure-Activity Relationship; Tomography, Emission-Computed | 2003 |